GSK–IE Biopharma and AI Specialization Launches at IE Tower

This December, students, faculty, and GSK leaders gathered on the 24th floor of the IE Tower to launch the GSK–IE Biopharma and AI Gateway Specialization; a new academic–industry collaboration designed to explore the scientific, technological, and strategic dimensions of modern drug development.

The session opened with remarks from Dean Ikhlaq Sidhu and David Barros-Aguirre, Head of Global Health Medicines R&D at GSK. Both underscored the importance of bridging two historically separate worlds: academic learning and industrial application.

Sidhu reflected on the structural shift already underway: "That world is over… Companies and universities are coming closer together, working on problems that can’t be divided between theory and practice."

Barros added: "This is the first time we do something like this. We believe this kind of program will open up doors, not just for students, but for the future of the industry. The world is changing, and the way we train for science and innovation has to change with it."

From Molecule to Market: A Systems-Level Education

The four-month specialization, is led by David Moure, who serves as the Academic Director of the program which runs from January to April, places students at the intersection of research, regulation, data, and delivery. Each phase of the pharmaceutical lifecycle becomes a site of exploration:

• Drug discovery and early research, where students examine how candidate molecules behave and how AI tools are accelerating the search process.
• Clinical trials and evidence generation, focusing on data validation, trial design, and the practical constraints that shape regulatory approval.
• Precision and personalized medicine, looking at biomarkers, patient data, and the computational tools that are beginning to redefine therapeutic targeting.
• Smart Manufacturing, where students will understand the key challenges in scaling up pharmaceutical manufacturing.
• Commercial strategy, to launch a drug into the market and ensure patient access. 

GSK mentors guide students through real scenarios and technical challenges, from streamlining regulatory compliance to addressing antibiotic resistance with AI-driven strategies.

AI, Trust, and the Human Factor

A roundtable during the launch, was moderated by David Moure, Academic Director of the specialization, who guided the discussion on the future of AI-driven biopharma innovation and featured Jorge Pou (Innovation and Commercial Acceleration Director, GSK Spain), David Yeregui Marcos del Blanco (IE faculty and HealthTech entrepreneur), Rubén Sánchez-García (IE faculty), and David Barros-Aguirre. 

The discussion highlighted emerging tensions in biopharma: fragmented data systems, regulatory complexity, and the evolving role of AI in decision-making. "Healthcare generates vast amounts of data”, Barros noted, “but it’s fragmented across systems. Making it usable means addressing trust, interoperability, and ownership."

Panelists agreed that AI has the potential to accelerate discovery, but only when paired with clear human judgement. Yeregui encouraged students to engage without hesitation: "There are no stupid questions. Your fresh perspective is often exactly what’s needed."

Pou closed the panel by noting that, "…this is the kind of programme we need to build the next generation of biotech leaders. People who can move between systems but also understand its complexity, and help bring real solutions."

The new GSK–IE Biopharma and AI Gateway Specialization reflects an evolving model for science education. One where students, researchers, and industry professionals work together to co-develop the skills and tools needed to advance therapeutics. It is designed not only to build technical fluency, but also to foster a new generation of health innovators who can operate across systems, disciplines, and industries to deliver more effective, personalized, and scalable treatments.